Kitamura S, Miyakawa K, Wakabayashi Y, Urabe A, Sato H, Ohbayashi Y, Takaku F, Togawa A, Shindo E, Aoki I
Third Department of Internal Medicine, University of Tokyo.
Jpn J Antibiot. 1993 May;46(5):374-87.
Fluconazole (FLCZ) was administered orally or intravenously to 161 patients with systemic fungal infections complicated with hematological disorders and it was possible to evaluate clinical efficacies in 109 patients. Systemic fungal infections were documented in 48 patients and suspected in 61 patients. The overall clinical efficiency rates were 43.8% (21/48) in patients with documented fungal infections, and 55.7% (34/61) in patients with suspected fungal infections. Therefore, the overall clinical efficacy rate was 50.5% (55/109). Side effects were observed in 5 patients with an incident rate of 3.1% (5/161), but there was none of them was serious. These results indicate that FLCZ is an agent with good potential in treatment of systemic fungal infections in patients with hematological disorders.
对161例合并血液系统疾病的系统性真菌感染患者口服或静脉给予氟康唑（FLCZ），并对其中109例患者的临床疗效进行了评估。确诊系统性真菌感染的患者有48例，疑似患者有61例。确诊真菌感染患者的总体临床有效率为43.8%（21/48），疑似真菌感染患者的总体临床有效率为55.7%（34/61）。因此，总体临床有效率为50.5%（55/109）。5例患者出现副作用，发生率为3.1%（5/161），但均不严重。这些结果表明，氟康唑在治疗合并血液系统疾病患者的系统性真菌感染方面具有良好的应用潜力。
